摘要
目的探讨不同亚型弥漫大B细胞淋巴瘤(DLBCL)组织中核转录因子κB(NF-κB)、原癌基因cMYC的表达及临床意义。方法用免疫组织化学方法检测57例弥漫大B细胞淋巴瘤患者组织NF-κB、cMYC的表达,并分析其与DLBCL的临床特征的关系。结果 NF-κB在DLBCL中表达与国际预后指数(IPI)及病理亚型有关,cMYC在DLBCL中表达与病理亚型有关。NF-κB在非生发中心/活化B细胞(non-GCB/ABC)亚型中的表达明显高于生发中心(GCB)亚型,它在ABC-DLBCL及GCB-DLBCL亚型组织中的阳性表达率分别为72.7%、41.6%,差异有统计学意义(P=0.029)。cMYC在ABC-DLBCL亚型中的表达明显高于GCB-DLBCL亚型,在ABC-DLBCL及GCB-DLBCL亚型组织中的阳性表达率分别为66.7%、54.4%,差异有统计学意义(P=0.035)。ABC-DLBCL亚型,NF-κB、cMYC的表达与生存相关。在GCB-DLBCL亚型中,NF-κB和cMYC的阳性或阴性表达与总生存不相关。结论 NF-κB、cMYC在ABC-DLBCL亚型表达率高于GCB-DLBCL亚型,同时可能是影响ABC-DLBCL亚型预后的不利因素。
Objective To investigate the clinical significance and expression of determination of nuclear transcription factor KB (NF-KB), and cellular myelocytomatosis oncogene (cMYC), in patients of different subtypes of diffuse large B cell lymphoma (DLBCL). Methods The expressions of NF-KB and cMYC in diffuse large B cell lymphoma in 57 cases were detected by immunohistochemistry. And its relationship with clinical pathological characteristics was analyzed. Results The positive expression of NF-KB was related with international prognosis index (IPI) and pathological subtype, pathological subtype the positive expression of cMYC was related with pathological subtype. The expression of NF-KB in ABC-DLBCL was significantly higher than that in GCB-DLBCL, positive rate of pathological subtypepathological subtypeits expression in ABC-DLBCL, GCB-DLBCL tissues were 72.7%, 41.6% respectively, there was significant dif- ference between two groups (P = 0.029). The expression of eMYC in ABC-DLBCL was significantly higher than that in GCB-DLBCL, its expression in ABC-DLBCL, GCB-DLBCL tissues were 66.7%, 54.4% respectively, there was statisti- cal difference between two groups (P = 0.035). In ABC-DLBCL subtype, the expression of NF-kB and cMYC were re- lated with overall survival. In GCB-DLBCL subtype, the expression of NF-KB and cMYC were not related with overall survival. Conclusion The expression of NF-KB and cMYC in ABC-DLBCL are significantly higher than those in GCB- DLBCL. In the same time, they may be adverse prognostic factors for ABC-DLBCL subtype.
出处
《中国医药导报》
CAS
2014年第11期10-13,共4页
China Medical Herald